This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2019 Jun;16(6):326.

doi: 10.1038/s41575-019-0155-5.

CT-P13 biosimilar is non-inferior to infliximab

Affiliations

PMID: 31053771
DOI: 10.1038/s41575-019-0155-5

Comment

CT-P13 biosimilar is non-inferior to infliximab

Iain Dickson. Nat Rev Gastroenterol Hepatol. 2019 Jun.

. 2019 Jun;16(6):326.

doi: 10.1038/s41575-019-0155-5.

Author

Affiliation

¹ Nature Reviews Gastroenterology & Hepatology, . nrgasthep@springernature.com.

PMID: 31053771
DOI: 10.1038/s41575-019-0155-5

No abstract available

PubMed Disclaimer

Comment on

Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study.
Ye BD, Pesegova M, Alexeeva O, Osipenko M, Lahat A, Dorofeyev A, Fishman S, Levchenko O, Cheon JH, Scribano ML, Mateescu RB, Lee KM, Eun CS, Lee SJ, Lee SY, Kim H, Schreiber S, Fowler H, Cheung R, Kim YH. Ye BD, et al. Lancet. 2019 Apr 27;393(10182):1699-1707. doi: 10.1016/S0140-6736(18)32196-2. Epub 2019 Mar 28. Lancet. 2019. PMID: 30929895 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Medical
- MedlinePlus Health Information